COVID-19 and diabetes. Possible role of polymorphism and rise of telemedicine

Publicado: 17-07-2025

Resumen

Background: Diabetes has been found to be one of the leading comorbidities associated with fatality in COVID-19 patients. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry is facilitated by interaction with Angiotensin Converting Enzyme-2 (ACE2) and possible polymorphisms in ACE2 can be a determining factor in host-viral protein interaction. A significant shift of healthcare towards "Telemedicine" is also on the rise. In this review, the possible effects of ACE2 polymorphisms on SARS-CoV-2 entry along with the escalation of "telemedicine" is discussed.


Method: An expansive literature search using keywords: "COVID-19", "SARS-CoV-2", "diabetes", "type 2 diabetes", "type 1 diabetes", "ACE2", "polymorphism", "DPP4" and "telemedicine" was conducted on Pubmed and EMBASE till 7th August 2020.


Result: Possible polymorphisms in ACE2 gene can play a role in influencing the virus entry in host body. Telemedicine can bring a new revolution for medical sector.


Conclusion: COVID-19 severity is more heinous among diabetic population. So far, the in-silico studies involving human ACE2-viral Spike (S) interaction showed inconsistent predictions regarding some SNPs. But without actual in-vivo studies, a holistic understanding can't be established. © 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Downloads

Download data is not yet available.

Detalles del artículo

Artículos similares

También puede Iniciar una búsqueda de similitud avanzada para este artículo.